Q-omics provides the consensus-scored SNORA70B profile across patient tissues and cancer cell-line models. SNORA70B expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNORA70B is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, SNORA70B RNA expression shows 6,974 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRC, COAD, and PCPG as cancer lineages where SNORA70B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA70B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA70B survival associations across molecular data types. SNORA70B RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA70B RNA expression–survival associations across cancer types. High SNORA70B expression shows unfavorable associations in KIRC, STAD, DLBC, ACC and LGG, but favorable associations in LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNORA70B RNA expression.
This table summarizes SNORA70B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA70B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA70B shows lower tumor expression in THCA and higher tumor expression in COAD and BRCA. The COAD box plot shows higher SNORA70B RNA expression in tumor versus normal tissue (log2 FC = +0.382, t-test p < 0.001).
This table shows molecular features associated with SNORA70B in patient tissues and cancer cell lines. In patient samples, SNORA70B shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set.
